upgrad ow
posit meaning benefit market shift
phase ii test share outperform
sinc earn see room upsid updat
estim consensu rais price target
rate ow
downgrad share thought test
enough off-set headwind associ declin physician offic visit
sinc done work re-evalu potenti opportun
rais estim pre forecast
compani posit benefit broaden test guidelin
new market opportun longer term continu see opportun
quest gain share expens region lab accordingli
upgrad share ow rais price target
quantifi diagnost opportun market debat
recent day center around serolog test opportun
analysi suggest diagnost test opportun may two time
higher consid ad test part pre elect procedur routin
sinc earli march suppli shortag limit test lead
restrict test guidelin patient highest acuiti effort
preserv suppli time suppli becom avail test
guidelin start expand expect meaning
benefit market evolut phase ii test paradigm
four wall hospit analysi suggest diagnost could
translat million revenu opportun million ebit
exhibit diagnost revenu opportun
employ return work program within quest wheel hous serolog
test critic compon reopen busi employ
develop return work program work nation lab
creat test program opportun go split among
suppli chain particip drug retail chain includ estim
 distribut unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
base consensu methodolog
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
million revenu opportun quest fall help off-set
declin core test time expect point care test
increasingli captur screen volum base case model
benefit less pronounc beyond exhibit
updat estim reflect benefit increment test
opportun updat model estim model
revenu billion ep compar ep
rais price target use sum part valuat framework
account relat profit stream next month assign
multipl estim compani core earn power
repres quest year averag discount
in-line prior valuat methodolog assign multipl
estim compani covid earn power higher multipl
combin compani core multipl increment multipl
point in-line averag pe multipl expans sinc market trough
rel compani benefit covid
fischer
opportun limit compani posit
benefit test marketplac transit phase includ labcorp
walgreen compani disclos yesterday market open
nation test site one medic
wrong point care test may account major
serolog market similar flu test bear case assum refer
lab account share hospit lab higher percent
diagnost test test volum may slower recov
upgrad ew ow increas pt
greater benefit test report quantifi
molecular test opportun well serolog opportun potenti
contribut total million quest diagnost revenu
thesi like differ rest market estim molecular
test opportun million time larger serolog test
opportun million
exhibit molecular serolog test billion revenu opportun next
next month
molecular/pcr test expand suppli avail improv over-tim
repres million opportun test suppli well
document issu hinder relat test due shortag key
materi nasal swab viral media year date million test
administ usa link quest account million total
molecular test phase test suppli constraint limit total test
capac cdc issu guidelin clear definit patient receiv
exhibit move phase phase test curv volum test expand address larger market
move phase phase test curv volum test
expand address larger market repres million total revenu
opportun quest compris test
symptomat asymptomat covid patient feedback expert call
presid region outreach lab see hospit resum elect
surgeri mandat execut molecular pcr test hr advanc
procedur estim could translat increment million test us
commerci lab next month billion market assum quest
account market in-line nation share repres
million revenu opportun see exhibit
alreadi sign begun shift phase phase test
seen recent test guidanc updat new york citi
announc walgreen start administr test
nationwid ultim shift phase test expect test open
gener public includ asymptomat patient increas quest
exhibit revenu opportun molecular/pcr test
serolog test key reopen economi get peopl back
work initi test made avail frontlin worker expect
larg employ individu cover commerci payor follow
initi phase expect serolog test split central refer lab
point care poc analysi estim aso group sign back
work program per test accord channel check
employ group may facilit program test test
segment market reimburs lower rate base
code dual-antibodi igg igm test see
analysi focus commerci popul assum
serolog test done commerci lab set market
share physician offic test assum remaind perform
point-of-car long-run believ serolog test longer
perform commerci lab shift toward poc resembl pattern
establish test influenza influenza test complet
point-of-car base channel check
exhibit serolog test repres million revenu opportun
note estim assum quest garner refer lab volum in-line share physician offic market
price assumpt earli may june frontlin
worker includ expos healthcar employe
receiv serolog test administ dual-antibodi
igg igm test reimburs per test
next phase employ return work assum
higher reimburs rate rang reflect
return work program accordingli averag
blend price increas
economi reopen number new covid case
declin need conduct igm test taper
result expect market shift single-antibodi
test igg-onli lower rate per test note
assum second surg would result new
covid case also lead dual-
iga igg igm test
immunoglobulin test antibodi test measur
presenc certain immunoglobulin ig
bodi igm igg commonli cite test
immunoglobulin iga antibodi found
respiratori tract digest system well
saliva tear breast milk
immunoglobulin igm found blood lymph
fluid first antibodi form fight new
infect high level igm repres recent
immunoglobulin igg common
antibodi bodi take longer-tim form
bodi exposur antigen high level
updat revenu estim exhibit
compar previou model
pre publish model largest contributor declin
revenu forecast lost routin physician test estim y/i
volum declin includ impact
higher unemploy tailwind includ serolog test
molecular covid test increas revenu larg due regain
routin physician offic test well molecular covid test
updat ep estim exhibit
compar previou model final
publish model covid routin physician test pama
repres signific headwind molecular covid test cost
cut initi repres largest tailwind increas
ep larg due regain routin physician offic test well
molecular covid test
valu quest sum part basi assign multipl estim
compani core earn power repres quest year averag
discount assign multipl estim
compani covid earn power base compani core multipl plu
averag pe multipl expans sinc market trough rel
 seen covid test compani includ abbott becton
dickinson thermo fischer
exhibit part analysi
morgan stanley research thomson reuter
exhibit trough multipl expans test compani
morgan stanley research thomson reuter
nt slowdown core test potenti off-set test
deriv multipl appli core earn power multipl appli
covid earn power
largest nation
lab market share physician lab
unit decis establish long-term
strateg partnership two nation
lab labcorp set
stage ration price provid
quest opportun gain market share
next three year
capit deploy form tuck-in
strategi cost cut program
invigor increas test mix toward
advanc molecular diagnost
near term slowdown physician ofc
visit meaning headwind
core test xed cost busi
view descript risk reward theme
multipl bull case ep
bear case multipl
bear case multipl deriv
minu year peak premium
 appli core earn power
multipl appli covid earn
power base core multipl plu
sinc market trough rel
 pseen covid test
base case ep
base case multipl
base case multipl deriv
minu year discount
appli core earn power
multipl appli covid earn power
base core multipl plu
market trough rel
 pseen covid test
multipl bear case ep
bear case multipl
bear case multipl deriv
minu year trough discount
 appli core earn power
multipl appli covid earn
power base core multipl plu
sinc market trough rel
 pseen covid test
volum growth move in-network
bcbsnj less scale region
player well prefer lab
view explan region hierarchi
research highest favor quintil
higher core volum growth faster
expect share gain region
revers pama cut
consolid driver higher benet
volum growth share gain meet
save program magnitud come
expect
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
